Corrigendum: Functional coupling of human microphysiology systems: Intestine, liver, kidney proximal tubule, blood-brain barrier and skeletal muscle (Scientific Reports (2017) 7 (42296) DOI: 10.1038/srep42296);Functional Coupling of Human Microphysiology Systems: Intestine, Liver, Kidney Proximal Tubule, Blood-Brain Barrier and Skeletal Muscle

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Vernetti, Lawrence ^a,b   Gough, Albert ^a,b   Baetz, Nicholas ^c   Blutt, Sarah ^d   Broughman, James R ^d   Brown, Jacquelyn A ^e   Foulke Abel, Jennifer ^c   Hasan, Nesrin ^c   In, Julie ^c   Kelly, Edward ^f   Kovbasnjuk, Olga ^c   Repper, Jonathan ^g   Senutovitch, Nina ^a   Stabb, Janet ^c   Yeung, Catherine ^f   Zachos, Nick C ^c   Donowitz, Mark ^c   Estes, Mary ^d   Himmelfarb, Jonathan ^f   Truskey, George ^g   Wikswo, John P ^e,h   Taylor, D Lansing ^a,b,i   more..

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Duke University   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; METHYLAMINE; TERFENADINE; TRIMETHYLAMINE;

ANTIBODY SPECIFICITY; BLOOD BRAIN BARRIER; DRUG EFFECT; HUMAN; INTESTINE; KIDNEY PROXIMAL TUBULE; LIVER; METABOLISM; METABOLOME; PHYSIOLOGY; SKELETAL MUSCLE; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CHOLECALCIFEROL; HUMANS; INTESTINES; KIDNEY TUBULES, PROXIMAL; LIVER; METABOLOME; METHYLAMINES; MUSCLE, SKELETAL; ORGAN SPECIFICITY; TERFENADINE;

EID: 85011797666     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44517     Document Type: Erratum

References (67)

1. Olson, H. et al. Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals. Regulatory Toxicology and Pharmacology 32, 56-67 (2000).
2. Perel, P. et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334, 197, doi: 10.1136/bmj.39048.407928.BE (2007).
3. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nature reviews. Clinical oncology 9, 338-350, doi: 10.1038/nrclinonc.2012.61 (2012).
4. Kerbel, R. S. et al. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast (Edinburgh, Scotland) 22, Suppl 2, S57-65, doi: 10.1016/j.breast.2013.07.011 (2013).
5. Nam, K. H., Smith, A. S., Lone, S., Kwon, S. & Kim, D. H. Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening. Journal of laboratory automation 20, 201-215, doi: 10.1177/2211068214557813 (2015).
6. Ouattara, D. A., Choi, S. H., Sakai, Y., Pery, A. R. & Brochot, C. Kinetic modelling of in vitro cell-based assays to characterize nonspecific bindings and ADME processes in a static and a perfused fluidic system. Toxicology letters 205, 310-319, doi: 10.1016/j. toxlet.2011.06.021 (2011).
7. Marx, U. et al. 'Human-on-a-chip' developments: a translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40, 235-257 (2012).
8. Prot, J. M. et al. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. International journal of pharmaceutics 408, 67-75, doi: 10.1016/j.ijpharm.2011.01.054 (2011).
9. Ouattara, D. A. et al. Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells. Molecular bioSystems 8, 1908-1920, doi: 10.1039/c2mb25049g (2012).
10. Skardal, A., Shupe, T. & Atala, A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug discovery today, doi: 10.1016/j.drudis.2016.07.003 (2016).
11. Polini, A. et al. Organs-on-a-chip: a new tool for drug discovery. Expert Opinion on Drug Discovery 9, 335-352, doi: 10.1517/1746 0441.2014.886562 (2014).
12. Benam, K. H. et al. Engineered in vitro disease models. Annu Rev Pathol 10, 195-262, doi: 10.1146/annurev-pathol-012414-040418 (2015).
13. Lee, S. H. et al. Microtechnology-based organ systems and whole-body models for drug screening. Biotechnology journal 11, 746-756, doi: 10.1002/biot.201500551 (2016).
14. Wagner, I. et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab on a chip 13, 3538-3547, doi: 10.1039/c3lc50234a (2013).
15. Oleaga, C. et al. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Scientific reports 6, 20030, doi: 10.1038/srep20030 (2016).
16. Iori, E. et al. Glucose and fatty acid metabolism in a 3 tissue in-vitro model challenged with normo- and hyperglycaemia. PloS one 7, e34704, doi: 10.1371/journal.pone.0034704 (2012).
17. Zhang, C., Zhao, Z., Abdul Rahim, N. A., van Noort, D. & Yu, H. Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. Lab on a chip 9, 3185-3192, doi: 10.1039/b915147h (2009).
18. Sung, J. H., Kam, C. & Shuler, M. L. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab on a chip 10, 446-455, doi: 10.1039/b917763a (2010).
19. Wikswo, J. P. et al. Engineering Challenges for Instrumenting and Controlling Integrated Organ-on-Chip Systems. IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING 60, 682-690, doi: 10.1109/TBME.2013.2244891 (2013).
20. Wikswo, J. P. et al. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab on a chip 13, 3496-3511, doi: 10.1039/ c3lc50243k (2013).
21. Paakkari, I. Cardiotoxicity of new antihistamines and cisapride. Toxicology letters 127, 279-284 (2002).
22. Ju, M. & Wray, D. Molecular identification and characterisation of the human eag2 potassium channel. FEBS letters 524, 204-210 (2002).
23. Tang, W. H. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116, 448-455, doi: 10.1161/CIRCRESAHA.116.305360 (2015).
24. Hindmarch, I., Shamsi, Z. & Kimber, S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology 32, 133-139 (2002).
25. Madden, L., Juhas, M., Kraus, W. E., Truskey, G. A. & Bursac, N. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. Elife 4, e04885, doi: 10.7554/eLife.04885 (2015).
26. Reboul, E. et al. Vitamin D intestinal absorption is not a simple passive diffusion: evidences for involvement of cholesterol transporters. Mol Nutr Food Res 55, 691-702, doi: 10.1002/mnfr.201000553 (2011).
27. Harms, L. R., Burne, T. H., Eyles, D. W. & McGrath, J. J. Vitamin D and the brain. Best practice & research. Clinical endocrinology & metabolism 25, 657-669, doi: 10.1016/j.beem.2011.05.009 (2011).
28. Haddad, J. G., Matsuoka, L. Y., Hollis, B. W., Hu, Y. Z. & Wortsman, J. Human plasma transport of vitamin D after its endogenous synthesis. Journal of Clinical Investigation 91, 2552-2555 (1993).
29. Zhang, A. Q., Mitchell, S. C. & Smith, R. L. Dietary precursors of trimethylamine in man: a pilot study. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 37, 515-520 (1999).
30. Wang, Z. et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell 163, 1585-1595, doi: 10.1016/j.cell.2015.11.055 (2015).
31. Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. The New England journal of medicine 368, 1575-1584, doi: 10.1056/NEJMoa1109400 (2013).
32. Missailidis, C. et al. Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. PloS one 11, e0141738, doi: 10.1371/journal.pone.0141738 (2016).
33. Cashman, J. R., Akerman, B. R., Forrest, S. M. & Treacy, E. P. Population-specific polymorphisms of the human FMO3 gene: significance for detoxication. Drug metabolism and disposition: the biological fate of chemicals 28, 169-173 (2000).
34. Handley, D. A., Magnetti, A. & Higgins, A. J. Therapeutic advantages of third generation antihistamines. Expert opinion on investigational drugs 7, 1045-1054, doi: 10.1517/13543784.7.7.1045 (1998).
35. Drici, M. D. & Barhanin, J. Cardiac K+ channels and drug-acquired long QT syndrome. Therapie 55, 185-193 (2000).
36. Crumb, W. J., Jr., Wible, B., Arnold, D. J., Payne, J. P. & Brown, A. M. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Molecular pharmacology 47, 181-190 (1995).
37. Zhou, S. et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical pharmacokinetics 44, 279-304 (2005).
38. Renwick, A. G. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 29 Suppl 3, 116-124 (1999).
39. Scherer, C. R. et al. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia. British journal of pharmacology 137, 892-900, doi: 10.1038/sj.bjp.0704873 (2002).
40. Brunette, M. G., Chan, M., Ferriere, C. & Roberts, K. D. Site of 1, 25(OH)2 vitamin D3 synthesis in the kidney. Nature 276, 287-289 (1978).
41. Heaney, R. P. et al. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. The American journal of clinical nutrition 87, 1738-1742 (2008).
42. Mawer, E. B., Backhouse, J., Holman, C. A., Lumb, G. A. & Stanbury, S. W. The distribution and storage of vitamin D and its metabolites in human tissues. Clinical science 43, 413-431 (1972).
43. Song, M. et al. Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study. Cancer prevention research (Philadelphia, Pa.) 9, 664-672, doi: 10.1158/1940-6207.capr-16-0053 (2016).
44. Futrega, K. et al. Polydimethylsiloxane (PDMS) modulates CD38 expression, absorbs retinoic acid and may perturb retinoid signalling. Lab on a chip 16, 1473-1483, doi: 10.1039/c6lc00269b (2016).
45. Regehr, K. J. et al. Biological implications of polydimethylsiloxane-based microfluidic cell culture. Lab on a chip 9, 2132-2139, doi: 10.1039/b903043c (2009).
46. Wang, J. D., Douville, N. J., Takayama, S. & ElSayed, M. Quantitative Analysis of Molecular Absorption into PDMS Microfluidic Channels. Ann Biomed Eng 40, 1862-1873, doi: 10.1007/s10439-012-0562-z (2012).
47. Yuan, S. et al. Enhanced biocompatibility of biostable poly(styrene-b-isobutylene-b-styrene) elastomer via poly(dopamine)-assisted chitosan/hyaluronic acid immobilization. RSC Advances 4, 31481-31488, doi: 10.1039/C4RA04523H (2014).
48. Borysiak, M. D. et al. Simple replica micromolding of biocompatible styrenic elastomers. Lab Chip 13, 2773-2784, doi: 10.1039/ c3lc50426c (2013).
49. Sackmann, E. K., Fulton, A. L. & Beebe, D. J. The present and future role of microfluidics in biomedical research. Nature 507, 181-189, doi: 10.1038/nature13118 (2014).
50. Roy, E., Galas, J. C. & Veres, T. Thermoplastic elastomers for microfluidics: towards a high-throughput fabrication method of multilayered microfluidic devices. Lab Chip 11, 3193-3196, doi: 10.1039/c1lc20251k (2011).
51. Markov, D. A., Lillie, E. M., Garbett, S. P. & McCawley, L. J. Variation in diffusion of gases through PDMS due to plasma surface treatment and storage conditions. Biomedical microdevices 16, 91-96, doi: 10.1007/s10544-013-9808-2 (2014).
52. Weber, E. J. et al. Development of a microphysiological model of human kidney proximal tubule function. Kidney International 90, 627-637, doi: 10.1016/j.kint.2016.06.011.
53. Vernetti, L. A. et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Experimental biology and medicine 241, 101-114, doi: 10.1177/1535370215592121 (2016).
54. Brown, J. A. et al. Recreating blood-brain barrier physiology and structure on chip: A novel neurovascular microfluidic bioreactor. Biomicrofluidics 9, 054124, doi: 10.1063/1.4934713 (2015).
55. VanDussen, K. L. et al. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut 64, 911-920, doi: 10.1136/gutjnl-2013-306651 (2015).
56. Robinson-Cohen, C. et al. Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients. PloS one 11, e0161074, doi: 10.1371/journal.pone.0161074 (2016).
57. Di, L. et al. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. Journal of biomolecular screening 8, 453-462, doi: 10.1177/1087057103255988 (2003).
58. Xu, R. et al. Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries. Journal of the American Society for Mass Spectrometry 13, 155-165, doi: 10.1016/s1044-0305(01)00342-7 (2002).
59. Ettayebi, K. et al. Replication of human noroviruses in stem cell-derived human enteroids. Science, doi: 10.1126/science.aaf5211 (2016).
60. Sato, T. & Clevers, H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340, 1190-1194, doi: 10.1126/science.1234852 (2013).
61. Saxena, K. et al. Human Intestinal Enteroids: a New Model To Study Human Rotavirus Infection, Host Restriction, and Pathophysiology. Journal of virology 90, 43-56, doi: 10.1128/jvi.01930-15 (2016).
62. Cucullo, L., Hossain, M., Puvenna, V., Marchi, N. & Janigro, D. The role of shear stress in Blood-Brain Barrier endothelial physiology. BMC Neurosci 12, 40, doi: 10.1186/1471-2202-12-40 (2011).
63. Germann, B., Neuhaus, W., Hofer-Warbinek, R. & Noe, C. R. Applying blood-brain barrier in vitro models to study the influence of drugs on endothelial cells-effects of selected COX-inhibitors. Pharmazie 63, 303-307 (2008).
64. Molino, Y., Jabes, F., Lacassagne, E., Gaudin, N. & Khrestchatisky, M. Setting-up an in vitro model of rat blood-brain barrier (BBB): a focus on BBB impermeability and receptor-mediated transport. J Vis Exp e51278, doi: 10.3791/51278 (2014).
65. Vandenhaute, E. et al. Modelling the neurovascular unit and the blood-brain barrier with the unique function of pericytes. Curr Neurovasc Res 8, 258-269, doi: 10.2174/156720211798121016#sthash.yGcQMKev.dpuf (2011).
66. Taguchi, K., Matsushita, M., Takahashi, M. & Uchino, J. Development of a bioartificial liver with sandwiched-cultured hepatocytes between two collagen gel layers. Artif Organs 20, 178-185 (1996).
67. Gough, A., V. L., Bergenthal, L., Shun, T.-Y. & Taylor, D. L. The microphysiology database for analyzing and modeling compound interactions with human and animal organ models. Applied In Vitro Toxicology 2, 103-117 (2016).